The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with <a href="https://www.biospace.com/article/fda-approves-novo-s-obesity-drug-wegovy-to-reduce-cardiovascular-events/" target="_blank" rel="noopener noreferer">label expansion</a>. 
Also discussed: biosimilar approvals for <a href="https://www.biospace.com/article/fresenius-kabi-s-biosimilar-for-actemra-gets-fda-approval/" target="_blank" rel="noopener noreferer">Fresenius Kabi</a>, and <a href="https://www.biospace.com/article/sandoz-nabs-fda-approvals-for-first-two-biosimilars-for-amgen-s-denosumab/" target="_blank" rel="noopener noreferer">Sandoz</a>.
More news at the forefront of <a href="https://www.biospace.com/article/deep-dive-leqembi-and-the-future-of-alzheimer-s-treatment/" target="_blank" rel="noopener noreferer">Alzheimer&#39;s treatment</a>: Eli Lilly&#39;s donanemab decision date <a href="https://www.biospace.com/article/lilly-s-donanemab-hit-with-surprise-delay-set-to-face-fda-adcomm/" target="_blank" rel="noopener noreferer">got pushed</a> and now the FDA wants to discuss the drug’s safety and efficacy at an <a href="https://www.biospace.com/article/unique-trial-design-expected-to-be-focus-of-upcoming-donanemab-adcomm/" target="_blank" rel="noopener noreferer">upcoming adcomm</a>. 
And finally, politics: President Biden&#39;s <a href="https://www.biospace.com/article/biden-turns-up-heat-on-big-pharma-s-drug-prices-in-state-of-the-union-address/" target="_blank" rel="noopener noreferer">State of the Union address</a> ruffles feathers as he strikes out at Big Pharma and drug prices, and how the industry is reacting to the election.

The unintended consequences of small molecules

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.